Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in marginal zone lymphoma (OLYMP-1)
2024-517476-38-00Phase 2Authorised
- Sponsor
- University Hospital Ulm
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in marginal zone B-cell lymphoma (MZL), Gastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissue, splenic marginal zone lymphoma (SMZL) and 1 more, sponsored by University Hospital Ulm. Primary endpoint: Complete response rate after induction therapy. Planned start Sep 2024; status: authorised.
02
Drugs
obinutuzumab
03
Conditions
marginal zone B-cell lymphoma (MZL)Gastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissuesplenic marginal zone lymphoma (SMZL)nodal marginal zone B-cell lymphoma (NMZL)
Beyond the preview
Go deeper on 2024-517476-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517476-38-00.